pembrolizumab Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 4924 1374853-91-4

Description:

MoleculeDescription

Synonyms:

  • pembrolizumab
  • keytruda
  • lambrolizumab
  • SCH-900475
  • MK-3475
A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 28, 2016 PMDA MSD K.K.
July 17, 2015 EMA Merck Sharp & Dohme Limited
Sept. 4, 2014 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1486.09 16.78 627 15741 64299 46605395
Product use in unapproved indication 574.93 16.78 370 15998 89903 46579791
Immune-mediated adverse reaction 509.95 16.78 85 16283 137 46669557
Pneumonitis 237.81 16.78 139 16229 28281 46641413
Immune-mediated hepatitis 190.64 16.78 44 16324 566 46669128
Hypothyroidism 178.24 16.78 120 16248 31218 46638476
Hepatitis 163.50 16.78 115 16253 32100 46637594
Colitis 152.66 16.78 117 16251 37230 46632464
Hypophysitis 150.09 16.78 43 16325 1350 46668344
Tubulointerstitial nephritis 136.10 16.78 77 16291 14711 46654983
Product use issue 133.37 16.78 165 16203 94479 46575215
Immune-mediated enterocolitis 132.90 16.78 30 16338 347 46669347
Autoimmune colitis 132.34 16.78 31 16337 427 46669267
Myocarditis 131.69 16.78 61 16307 7678 46662016
Tumour pseudoprogression 126.20 16.78 25 16343 144 46669550
Death 125.26 16.78 326 16042 335222 46334472
Autoimmune hypothyroidism 110.06 16.78 21 16347 96 46669598
Fulminant type 1 diabetes mellitus 105.03 16.78 23 16345 229 46669465
Adverse event 103.63 16.78 90 16278 34094 46635600
Thyroiditis 97.07 16.78 32 16336 1616 46668078
Off label use 96.57 16.78 322 16046 379519 46290175
Type 1 diabetes mellitus 93.34 16.78 36 16332 2874 46666820
Vitiligo 92.87 16.78 28 16340 1053 46668641
Immune-mediated hypothyroidism 85.51 16.78 13 16355 6 46669688
Adrenal insufficiency 83.66 16.78 54 16314 13070 46656624
Autoimmune hepatitis 80.95 16.78 44 16324 7770 46661924
Adrenocorticotropic hormone deficiency 76.00 16.78 17 16351 188 46669506
Hyperthyroidism 74.19 16.78 48 16320 11663 46658031
Nephritis 69.30 16.78 26 16342 1924 46667770
Lichenoid keratosis 67.44 16.78 23 16345 1290 46668404
Autoimmune thyroiditis 65.37 16.78 28 16340 2927 46666767
Myasthenia gravis 64.24 16.78 29 16339 3437 46666257
Immune-mediated arthritis 59.30 16.78 9 16359 4 46669690
Immune-mediated myocarditis 58.93 16.78 10 16358 19 46669675
Drug hypersensitivity 58.72 16.78 8 16360 243817 46425877
Immune-mediated pancreatitis 58.06 16.78 11 16357 48 46669646
Myositis 56.57 16.78 35 16333 7869 46661825
Cholestasis 55.06 16.78 57 16311 26836 46642858
Metastatic malignant melanoma 51.72 16.78 19 16349 1325 46668369
Inappropriate schedule of product administration 51.11 16.78 86 16282 64927 46604767
Therapy partial responder 50.27 16.78 27 16341 4655 46665039
Autoimmune arthritis 49.90 16.78 9 16359 28 46669666
Secondary adrenocortical insufficiency 47.58 16.78 16 16352 859 46668835
Hepatocellular injury 47.28 16.78 55 16313 29467 46640227
Drug ineffective 46.61 16.78 106 16262 677732 45991962
Immune-mediated hepatic disorder 46.54 16.78 8 16360 17 46669677
Drug effective for unapproved indication 45.65 16.78 18 16350 1524 46668170
Polymyalgia rheumatica 44.69 16.78 20 16348 2322 46667372
Immune-mediated thyroiditis 43.36 16.78 7 16361 8 46669686
Hypopituitarism 42.01 16.78 14 16354 731 46668963
Uveitis 41.84 16.78 30 16338 8611 46661083
Immune-mediated dermatitis 41.74 16.78 6 16362 0 46669694
Diabetic ketoacidosis 41.67 16.78 41 16327 18169 46651525
Immune-mediated nephritis 41.17 16.78 8 16360 41 46669653
Autoimmune nephritis 39.35 16.78 11 16357 315 46669379
Immune-mediated hyperthyroidism 39.31 16.78 6 16362 3 46669691
Autoimmune pancreatitis 38.91 16.78 10 16358 206 46669488
Rheumatoid arthritis 37.06 16.78 19 16349 240196 46429498
Pyrexia 36.67 16.78 228 16140 348574 46321120
Lichen planus 36.09 16.78 16 16352 1817 46667877
Lymphocytic hypophysitis 35.37 16.78 9 16359 178 46669516
Fall 35.36 16.78 38 16330 329059 46340635
Metastases to central nervous system 34.90 16.78 30 16338 11191 46658503
Eosinophilic fasciitis 34.79 16.78 8 16360 101 46669593
Hepatic function abnormal 34.62 16.78 51 16317 34370 46635324
Dizziness 33.67 16.78 42 16326 340372 46329322
Drug interaction 32.94 16.78 15 16353 203079 46466615
Pemphigoid 32.81 16.78 22 16346 5669 46664025
Neurofibrosarcoma 32.15 16.78 8 16360 144 46669550
Tumour associated fever 31.45 16.78 8 16360 158 46669536
Amputation stump pain 30.83 16.78 6 16362 31 46669663
Subacute cutaneous lupus erythematosus 29.20 16.78 14 16354 1901 46667793
Polyglandular autoimmune syndrome type II 29.03 16.78 6 16362 44 46669650
Nasopharyngitis 28.93 16.78 9 16359 153989 46515705
Hepatitis toxic 28.61 16.78 16 16352 2984 46666710
Autoimmune myocarditis 28.15 16.78 6 16362 52 46669642
Autoimmune endocrine disorder 27.83 16.78 4 16364 0 46669694
Immune-mediated endocrinopathy 27.83 16.78 4 16364 0 46669694
Transaminases increased 27.72 16.78 41 16327 27720 46641974
Blood thyroid stimulating hormone increased 27.55 16.78 20 16348 5849 46663845
Exposure during pregnancy 27.36 16.78 3 16365 108209 46561485
Joint swelling 27.34 16.78 12 16356 166061 46503633
Interstitial lung disease 27.08 16.78 59 16309 53890 46615804
Oligodipsia 26.00 16.78 5 16363 24 46669670
Immune-mediated neuropathy 25.59 16.78 4 16364 3 46669691
Radiation pneumonitis 24.83 16.78 11 16357 1246 46668448
Aspartate aminotransferase increased 24.71 16.78 72 16296 78628 46591066
Silent thyroiditis 24.52 16.78 5 16363 34 46669660
Sinusitis 23.63 16.78 8 16360 129760 46539934
Alanine aminotransferase increased 23.20 16.78 76 16292 88375 46581319
Skin toxicity 23.19 16.78 15 16353 3639 46666055
Autoimmune dermatitis 23.09 16.78 5 16363 47 46669647
Pericardial effusion 23.06 16.78 36 16332 25507 46644187
Pulmonary embolism 23.05 16.78 87 16281 108498 46561196
Antinuclear antibody 22.60 16.78 8 16360 501 46669193
Headache 22.51 16.78 89 16279 478263 46191431
Toxic epidermal necrolysis 22.38 16.78 33 16335 22245 46647449
Drug intolerance 22.11 16.78 12 16356 147037 46522657
Toxicity to various agents 22.11 16.78 25 16343 211741 46457953
Meningitis aseptic 21.76 16.78 15 16353 4044 46665650
Pulmonary sarcoidosis 21.69 16.78 9 16359 869 46668825
Autoimmune uveitis 21.60 16.78 4 16364 15 46669679
Vesical fistula 21.14 16.78 5 16363 72 46669622
Overdose 20.95 16.78 5 16363 101974 46567720
Hepatotoxicity 20.87 16.78 34 16334 24975 46644719
Sarcoidosis 20.69 16.78 16 16352 5143 46664551
Melanoma recurrent 20.59 16.78 5 16363 81 46669613
Neoplasm progression 20.56 16.78 35 16333 26648 46643046
Cholangitis sclerosing 20.43 16.78 9 16359 1006 46668688
Cytokine release syndrome 20.09 16.78 17 16351 6206 46663488
Asthma 19.79 16.78 4 16364 91538 46578156
Rash maculo-papular 19.44 16.78 35 16333 27839 46641855
Nephropathy toxic 19.36 16.78 18 16350 7436 46662258
Thyroid hormones increased 19.19 16.78 6 16362 255 46669439
Loss of consciousness 19.15 16.78 7 16361 108231 46561463
Abdominal discomfort 19.11 16.78 15 16353 151150 46518544
Renal tubular necrosis 18.84 16.78 21 16347 10738 46658956
Urogenital fistula 18.57 16.78 5 16363 124 46669570
Bronchitis 18.50 16.78 7 16361 105972 46563722
Cholecystitis 18.39 16.78 24 16344 14442 46655252
Serous retinal detachment 18.39 16.78 5 16363 129 46669565
Adenocarcinoma 18.30 16.78 11 16357 2348 46667346
Blood pressure abnormal 18.29 16.78 22 16346 12195 46657499
Immune-mediated myositis 18.05 16.78 8 16360 908 46668786
Pleural effusion 18.04 16.78 67 16301 82885 46586809
Vital functions abnormal 17.97 16.78 6 16362 315 46669379
No adverse event 17.82 16.78 38 16330 34193 46635501
Condition aggravated 17.82 16.78 37 16331 245015 46424679
Cholangitis 17.68 16.78 14 16354 4660 46665034
SJS-TEN overlap 17.60 16.78 5 16363 152 46669542
Achromotrichia acquired 17.58 16.78 3 16365 6 46669688
Pneumonia moraxella 17.51 16.78 4 16364 49 46669645
Radiation associated pain 17.51 16.78 4 16364 49 46669645
Cheilitis 17.39 16.78 13 16355 3975 46665719
Autoimmune thyroid disorder 17.26 16.78 3 16365 7 46669687
Roseolovirus test positive 17.15 16.78 4 16364 54 46669640
Myasthenia gravis crisis 17.00 16.78 6 16362 373 46669321

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1921.10 15.40 984 21981 71303 29858210
Immune-mediated adverse reaction 912.45 15.40 176 22789 300 29929213
Product use in unapproved indication 475.86 15.40 417 22548 73276 29856237
Pneumonitis 390.84 15.40 250 22715 27204 29902309
Interstitial lung disease 309.11 15.40 300 22665 59897 29869616
Adverse event 213.92 15.40 138 22827 15203 29914310
Myasthenia gravis 213.70 15.40 82 22883 2910 29926603
Adrenal insufficiency 202.16 15.40 116 22849 10347 29919166
Hypothyroidism 190.10 15.40 127 22838 14836 29914677
Immune-mediated hepatitis 187.47 15.40 58 22907 1058 29928455
Product use issue 181.13 15.40 199 22766 45817 29883696
Immune-mediated enterocolitis 177.53 15.40 55 22910 1008 29928505
Colitis 164.33 15.40 157 22808 30663 29898850
Type 1 diabetes mellitus 157.36 15.40 70 22895 3629 29925884
Off label use 156.83 15.40 482 22483 248808 29680705
Myocarditis 154.37 15.40 96 22869 9915 29919598
Tumour pseudoprogression 151.17 15.40 38 22927 306 29929207
Hypophysitis 150.80 15.40 56 22909 1812 29927701
Immune-mediated myocarditis 147.59 15.40 29 22936 57 29929456
Autoimmune hepatitis 139.57 15.40 64 22901 3563 29925950
Autoimmune colitis 127.22 15.40 40 22925 771 29928742
Vitiligo 120.20 15.40 37 22928 663 29928850
Immune-mediated hypothyroidism 114.53 15.40 19 22946 3 29929510
Myositis 110.41 15.40 79 22886 10298 29919215
Immune-mediated hepatic disorder 108.73 15.40 21 22944 36 29929477
Therapy partial responder 102.25 15.40 52 22913 3639 29925874
Tubulointerstitial nephritis 100.77 15.40 94 22871 17797 29911716
Pemphigoid 98.24 15.40 65 22900 7463 29922050
Hyperthyroidism 89.26 15.40 63 22902 8035 29921478
Immune-mediated arthritis 85.40 15.40 16 22949 21 29929492
Thyroiditis 79.61 15.40 34 22931 1595 29927918
Drug interaction 79.52 15.40 27 22938 199541 29729972
Immune-mediated myositis 73.49 15.40 30 22935 1255 29928258
Adrenocorticotropic hormone deficiency 70.36 15.40 22 22943 416 29929097
Inappropriate schedule of product administration 68.40 15.40 115 22850 39613 29889900
Death 68.15 15.40 487 22478 356796 29572717
Hepatitis 66.75 15.40 84 22881 22272 29907241
Nephritis 65.15 15.40 32 22933 2078 29927435
Completed suicide 63.69 15.40 3 22962 99489 29830024
Polymyalgia rheumatica 60.74 15.40 25 22940 1068 29928445
Fall 53.58 15.40 37 22928 181835 29747678
Organising pneumonia 52.52 15.40 38 22927 5036 29924477
Autoimmune hypothyroidism 52.45 15.40 11 22954 34 29929479
Autoimmune thyroiditis 52.20 15.40 22 22943 998 29928515
Hypopituitarism 51.57 15.40 25 22940 1577 29927936
Autoimmune arthritis 51.29 15.40 11 22954 39 29929474
Overdose 46.94 15.40 5 22960 84332 29845181
Immune-mediated uveitis 46.85 15.40 8 22957 3 29929510
Hepatic function abnormal 46.85 15.40 101 22864 41844 29887669
Secondary adrenocortical insufficiency 45.68 15.40 20 22945 997 29928516
Autoimmune myocarditis 45.59 15.40 12 22953 118 29929395
Metastatic malignant melanoma 45.52 15.40 25 22940 2045 29927468
Diabetic ketoacidosis 44.46 15.40 58 22907 15928 29913585
Eyelid ptosis 42.95 15.40 34 22931 5154 29924359
Fulminant type 1 diabetes mellitus 42.63 15.40 16 22949 533 29928980
Cholangitis sclerosing 41.02 15.40 18 22947 902 29928611
Immune-mediated thyroiditis 40.73 15.40 7 22958 3 29929510
Lichenoid keratosis 39.84 15.40 23 22942 2071 29927442
Immune-mediated pancreatitis 39.39 15.40 8 22957 20 29929493
Lymphocytic hypophysitis 38.52 15.40 11 22954 150 29929363
Autoimmune nephritis 37.36 15.40 11 22954 168 29929345
Rash 37.19 15.40 263 22702 191626 29737887
Hepatocellular injury 36.42 15.40 68 22897 25403 29904110
Haemophagocytic lymphohistiocytosis 36.14 15.40 41 22924 9750 29919763
Lung disorder 35.39 15.40 76 22889 31393 29898120
Diarrhoea 35.33 15.40 401 22564 333702 29595811
Drug effective for unapproved indication 34.92 15.40 17 22948 1082 29928431
Encephalitis autoimmune 34.64 15.40 13 22952 433 29929080
Pneumonia bacterial 34.07 15.40 39 22926 9364 29920149
Immune thrombocytopenia 33.63 15.40 35 22930 7556 29921957
Encephalitis 32.77 15.40 32 22933 6404 29923109
Autoimmune pancreatitis 32.52 15.40 11 22954 269 29929244
Immune-mediated dermatitis 31.97 15.40 6 22959 8 29929505
Toxicity to various agents 31.26 15.40 55 22910 177128 29752385
Immune-mediated endocrinopathy 30.87 15.40 5 22960 0 29929513
Tumour hyperprogression 30.81 15.40 6 22959 11 29929502
Paraneoplastic neurological syndrome 30.81 15.40 6 22959 11 29929502
Dizziness 30.48 15.40 65 22900 194844 29734669
Immune-mediated nephritis 29.58 15.40 8 22957 88 29929425
Immune-mediated renal disorder 28.52 15.40 5 22960 3 29929510
Autoimmune uveitis 28.52 15.40 5 22960 3 29929510
Skin toxicity 28.42 15.40 22 22943 3227 29926286
Melanoma recurrent 28.36 15.40 8 22957 104 29929409
Neoplasm progression 28.15 15.40 50 22915 17973 29911540
Silent thyroiditis 27.82 15.40 6 22959 22 29929491
Metastases to central nervous system 27.73 15.40 31 22934 7253 29922260
Immune-mediated encephalitis 27.61 15.40 6 22959 23 29929490
Thyroid disorder 27.35 15.40 20 22945 2694 29926819
Cancer pain 26.49 15.40 19 22946 2483 29927030
Plasma cell myeloma 25.50 15.40 5 22960 53457 29876056
Haemoglobin decreased 25.45 15.40 30 22935 114068 29815445
Drug ineffective 24.95 15.40 156 22809 340231 29589282
Enteritis 24.82 15.40 28 22937 6617 29922896
Drug hypersensitivity 24.37 15.40 11 22954 68508 29861005
Eosinophilic fasciitis 24.08 15.40 7 22958 102 29929411
Hypotension 23.65 15.40 77 22888 200488 29729025
Headache 23.62 15.40 67 22898 182239 29747274
Hypothalamo-pituitary disorder 23.60 15.40 11 22954 635 29928878
Cutaneous sarcoidosis 23.53 15.40 7 22958 111 29929402
Rheumatoid nodule 23.03 15.40 15 22950 1675 29927838
Anxiety 23.00 15.40 21 22944 89850 29839663
Insomnia 22.51 15.40 23 22942 93313 29836200
Depression 22.13 15.40 22 22943 90415 29839098
Decreased appetite 22.10 15.40 193 22772 149717 29779796
Pulmonary sarcoidosis 21.48 15.40 10 22955 576 29928937
Hospitalisation 21.44 15.40 4 22961 44315 29885198
Cardiac arrest 21.14 15.40 24 22941 92826 29836687
Dermatomyositis 21.12 15.40 12 22953 1048 29928465
Colitis microscopic 20.52 15.40 14 22951 1689 29927824
Lichen planus 20.39 15.40 11 22954 868 29928645
Agitation 20.32 15.40 8 22957 54065 29875448
Pericarditis malignant 20.31 15.40 4 22961 8 29929505
Primary hypothyroidism 20.03 15.40 5 22960 39 29929474
Mucosal inflammation 19.96 15.40 60 22905 30434 29899079
Latent autoimmune diabetes in adults 19.70 15.40 5 22960 42 29929471
Cholangitis 19.68 15.40 27 22938 7775 29921738
Autoimmune neuropathy 19.49 15.40 5 22960 44 29929469
Respiratory failure 19.47 15.40 138 22827 100504 29829009
Adrenalitis 19.16 15.40 4 22961 12 29929501
Lymph node abscess 19.16 15.40 4 22961 12 29929501
Pancreatic failure 19.09 15.40 10 22955 744 29928769
Transitional cell carcinoma recurrent 18.69 15.40 4 22961 14 29929499
Tumour ulceration 18.66 15.40 5 22960 53 29929460
Pyrexia 18.65 15.40 323 22642 294166 29635347
Autoimmune cholangitis 18.52 15.40 3 22962 0 29929513
Non-small cell lung cancer stage III 18.52 15.40 3 22962 0 29929513
Optic neuritis 18.21 15.40 17 22948 3217 29926296
Cardiac tamponade 18.08 15.40 20 22945 4624 29924889
International normalised ratio increased 18.04 15.40 7 22958 47732 29881781
Drug-induced liver injury 18.02 15.40 46 22919 21228 29908285
Fatigue 17.96 15.40 345 22620 320328 29609185
Limbic encephalitis 17.75 15.40 7 22958 267 29929246
Pleural effusion 17.63 15.40 107 22858 73959 29855554
Blood corticotrophin decreased 17.50 15.40 6 22959 153 29929360
Hallucination 17.25 15.40 8 22957 49051 29880462
Hepatotoxicity 17.24 15.40 41 22924 18104 29911409
Hypersensitivity 17.23 15.40 10 22955 54018 29875495
Syncope 17.19 15.40 24 22941 84879 29844634
Bradycardia 17.14 15.40 15 22950 65511 29864002
Hepatitis E virus test positive 17.08 15.40 4 22961 23 29929490
Autoimmune disorder 17.02 15.40 12 22953 1527 29927986
Cachexia 16.86 15.40 23 22942 6588 29922925
Toxic epidermal necrolysis 16.47 15.40 40 22925 17900 29911613
Radiation pneumonitis 16.35 15.40 13 22952 1983 29927530
Pain in extremity 16.18 15.40 38 22927 110183 29819330
Non-small cell lung cancer 16.17 15.40 17 22948 3713 29925800
Transaminases increased 16.15 15.40 47 22918 23410 29906103
Pruritus 15.78 15.40 149 22816 118055 29811458
Metastases to skin 15.55 15.40 7 22958 373 29929140
Melaena 15.54 15.40 3 22962 32434 29897079
Liver disorder 15.40 15.40 54 22911 29668 29899845

Pharmacologic Action:

SourceCodeDescription
ATC L01XC18 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Monoclonal antibodies
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
FDA MoA N0000191259 Programmed Death Receptor-1-directed Antibody Interactions
FDA EPC N0000191260 Programmed Death Receptor-1 Blocking Antibody

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908
Malignant tumor of head and/or neck indication 255056009
Metastatic malignant melanoma indication 443493003
Metastatic renal cell carcinoma indication 702392008

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Programmed cell death protein 1 Membrane receptor ANTIBODY BINDING Kd 10 IUPHAR DRUG LABEL

External reference:

IDSource
D10574 KEGG_DRUG
4033703 VUID
N0000191088 NUI
4033703 VANDF
C3855203 UMLSCUI
CHEMBL3137343 ChEMBL_ID
DB09037 DRUGBANK_ID
C582435 MESH_SUPPLEMENTAL_RECORD_UI
7499 IUPHAR_LIGAND_ID
9798 INN_ID
DPT0O3T46P UNII
1547545 RXNORM
228586 MMSL
30533 MMSL
d08287 MMSL
015666 NDDF
716125002 SNOMEDCT_US
763541003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KEYTRUDA HUMAN PRESCRIPTION DRUG LABEL 1 0006-3026 INJECTION, SOLUTION 25 mg INTRAVENOUS BLA 28 sections
KEYTRUDA HUMAN PRESCRIPTION DRUG LABEL 1 0006-3026 INJECTION, SOLUTION 25 mg INTRAVENOUS BLA 28 sections
KEYTRUDA HUMAN PRESCRIPTION DRUG LABEL 1 0006-3029 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections
KEYTRUDA HUMAN PRESCRIPTION DRUG LABEL 1 0006-3029 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections